<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34890069</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>291</StartPage><EndPage>302</EndPage><MedlinePgn>291-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27472</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC-NTF), a novel autologous cell-therapy capable of targeting multiple pathways, could safely slow ALS disease progression.</AbstractText><AbstractText Label="METHODS">This randomized, double-blind, placebo-controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS-R) &#x2265;25 (screening) and&#x2009;&#x2265;3 ALSFRS-R points decline prior to randomization. Participants received three treatments of MSC-NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC-NTF through a responder analysis and safety. A change in disease progression post-treatment of &#x2265;1.25&#x2009;points/mo defines a clinical response. A pre-specified analysis leveraged baseline ALSFRS-R of 35 as a subgroup threshold.</AbstractText><AbstractText Label="RESULTS">Overall, MSC-NTF treatment was well tolerated; there were no safety concerns. Thirty-three percent of MSC-NTF and 28% of placebo participants met clinical response criteria at 28&#x2009;wk (odds ratio [OR]&#xa0;=&#xa0;1.33, P&#xa0;=&#xa0;.45); thus, the primary endpoint was not met. A pre-specified analysis of participants with baseline ALSFRS-R&#x2009;&#x2265;&#x2009;35 (n&#xa0;=&#xa0;58) showed a clinical response rate at 28&#x2009;wk of 35% MSC-NTF and 16% placebo (OR&#xa0;=&#xa0;2.6, P&#xa0;=&#xa0;.29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC-NTF, with placebo unchanged.</AbstractText><AbstractText Label="DISCUSSION">The study did not reach statistical significance on the primary endpoint. However, a pre-specified subgroup suggests that MSC-NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.</AbstractText><CopyrightInformation>&#xa9; 2021 BrainStorm Cell Therapeutics. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Healey Center, Mass General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindborg</LastName><ForeName>Stacy R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-0103-2552</Identifier><AffiliationInfo><Affiliation>Research and Development, Brainstorm Cell Therapeutics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>UCI Health ALS &amp; Neuromuscular Center, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Sutter Pacific Medical Foundation, California Pacific Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burford</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Healey Center, Mass General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katharine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Healey Center, Mass General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozaffar</LastName><ForeName>Tahseen</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1230-0188</Identifier><AffiliationInfo><Affiliation>UCI Health ALS &amp; Neuromuscular Center, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Sutter Pacific Medical Foundation, California Pacific Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Liberty J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Sutter Pacific Medical Foundation, California Pacific Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-1140-4575</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owegi</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neurology Department, University of Massachusetts Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Donald A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Berry Consultants, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gothelf</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research and Development, Brainstorm Cell Therapeutics, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Yossef S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Manufacturing, Brainstorm Cell Therapeutics, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aricha</LastName><ForeName>Revital</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research and Development, Brainstorm Cell Therapeutics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Ralph Z</ForeName><Initials>RZ</Initials><AffiliationInfo><Affiliation>Research and Development, Brainstorm Cell Therapeutics, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windebank</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-6062-1528</Identifier><AffiliationInfo><Affiliation>Neurology Department, University of Massachusetts Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Muscle Nerve. 2022 Oct;66(4):E26-E27</RefSource><PMID Version="1">35960989</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList><CoiStatement>D.A.B. reports personal fees from Brainstorm Cell Therapeutics. J.D.B. reports personal fees from Biogen, Clene Nanomedicine, MT Pharma of America, MT Pharma Holdings of America, Janssen; grants from Alexion, Biogen, Amylyx Therapeutics, MT Pharma of America, Anelixis Therapeutics, Genentech, Rapa Therapeutics, MT Pharma Holdings of America, nQ Medical, NINDS, Muscular Dystrophy Association, ALS One, ALS Association, ALS Finding A Cure, Rapa Therapeutics; and has equity in ReactNeuro. J.K. reports consulting fees from MT Pharma, Denali Therapeutics, Biogen, Genetech, Amylyx, Cytokinetics, Wave, and Calico. K.N. reports personal fees from Alector LLC, AI Therapeutics, Biogen, Biohaven, MT Pharma, Wave Therapeutics, Enclear, and Regeneron; grants from ALS Association, Muscular Dystrophy Association, ALS Finding a Cure, and Target ALS. M.C. reports personal fees from Lilly Avexis, Pontifax, Orion, MT Pharma, Denali, Biogen, Pharmnext, Treeway, Revalasio, Takeda, Aclipse, Biohaven, Sunovian, Anelixis, Disarm, ALS Biopharma, Cytokinetics, RRD, Immunity Pharma, Helixsmith, Wave, Transposon, Quralis, Faze, Regeneron, and AB Sciences. N.A.G. received research support from Alexion, Brainstorm Cell Therapeutics, Cytokinetics, Fulcrum, Healey Platform, Kezar, Medicinova, Octapharma, Orion, Orphazyme; served on Advisory Boards for Acceleron, Alexion, Argenx, CSL Behring, MT Pharma, Sanofi Genzyme, Sarepta, UCB; received travel reimbursement and honoraria; and served on the speaker's bureau for CSL. N.P.S. reports research support from the National Institutes of Health (R01 CA21887), Regenerative Medicine Minnesota, Target ALS, and ALS Association. R.H.B. Jr. reports personal fees from Wave Lifesciences and serves on advisory boards of ALS Finding a Cure, Project ALS, and NEALS. R.L. received research support from&#xa0;Argenx, Annexon, Biotest, CSL Behring, Grifols, Pharnext, Sanofi&#x2010;Genzyme, Seattle Genetics, UCB, and Pfizer; honoraria from Medscape, Alnylam, Akcea; and served on advisory boards for GBS&#x2010;CIDP Foundation International, Myasthenia Gravis Foundation of America, MGF of California, and Board of Directors for Peripheral Nerve Society. S.R.L., R.K., Y.G, Y.S.L., and R.A are employees of and hold stock in Brainstorm Cell Therapeutics. A.J.W., L.J., M.A.O., M.B., R.M., and T.M. have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34890069</ArticleId><ArticleId IdType="pmc">PMC9305113</ArticleId><ArticleId IdType="doi">10.1002/mus.27472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26(suppl 9):S191&#x2010;S197. doi:10.37765/ajmc.2020.88483</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/ajmc.2020.88483</ArticleId><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31(5):635&#x2010;639. doi:10.1097/WCO.0000000000000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi G, Corti S. Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral&#xa0;sclerosis. Mol Neurobiol. 2019;56(10):6703&#x2010;6715. doi:10.1007/s12035-019-1554-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1554-x</ArticleId><ArticleId IdType="pubmed">30911936</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology. 2019;93(24):e2294&#x2010;e2305. doi:10.1212/WNL.0000000000008620</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of Mesenchymal stem cells secreting Neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73(3):337&#x2010;344. doi:10.1001/jamaneurol.2015.4321</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4321</ArticleId><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2010;299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169:13&#x2010;21. doi:10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162&#x2010;168. doi:10.3109/21678421.2012.762930</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat. 2004;58(1):16&#x2010;24. doi:10.1198/0003130042854</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/0003130042854</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7:1&#x2010;8. doi:10.1002/brb3.637</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009;89(2):607&#x2010;648. doi:10.1152/physrev.00031.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00031.2008</ArticleId><ArticleId IdType="pubmed">19342615</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Allen SP, Goodall EF, et al. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia&#x2010;response and RNA processing functions. Neuropathol Appl Neurobiol. 2015;41(2):201&#x2010;226. doi:10.1111/nan.12147</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12147</ArticleId><ArticleId IdType="pmc">PMC4329387</ArticleId><ArticleId IdType="pubmed">24750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90(12):1338&#x2010;1346. doi:10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and meta&#x2010;analysis. JAMA Neurol. 2019;76(9):1035&#x2010;1048. doi:10.1001/jamaneurol.2019.1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2019;9:1167. doi:10.3389/fneur.2018.01167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156&#x2010;166. doi:10.1002/mus.26801</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H&#x2010;J, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Brown RH, Aricha R, et al. CSF biomarker correlations with primary outcome in NurOwn phase 3 clinical trial. Presented by Berry JD at Northeast Amyotrophic Lateral Sclerosis Consortium&#xae; (NEALS). 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>